Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In … – Nasdaq
|
Inovio's Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In …
Nasdaq PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer … |
